Mr. Jongen founded IBA with the vision to advance particle therapy by inventing and developing a cyclotron particle accelerator, which could accelerate charged particles up to half the speed of light through a magnetic field. His vision and dedication were rewarded in 1994 when Massachusetts General Hospital commissioned IBA’s first cyclotron for proton therapy. This resulted in MGH treating its first patient in 2001 with IBA Proteus®, the first commercially available proton therapy system.

Convinced that cost was the largest impediment to making proton therapy available to more patients, Yves focused his attention on the development of a compact, energy-efficient proton therapy system, resulting in the development of a single room solution for IBA that dramatically reduced the total project cost associated with establishing a proton therapy center.

Dr. Nancy Mendenhall of the University of Florida Health Proton Therapy Institute states, “It would be difficult to think of anyone living who has been passionately interested in particle therapy longer than Yves. From his work in electrical engineering and physics in his early career and his early recognition of the potential value of protons for cancer treatment, Yves has worked tirelessly and creatively to develop technology to deliver proton therapy safely, effectively, and as inexpensively as possible”

Dr. Laramore’s vision that particle therapy would be at the forefront of the future of radiation therapy has been instrumental to the development of the field as it exists today.  His vision combined with his steadfast perseverance to make particle therapy available in the Pacific Northwestern United States has and continues to benefit thousands of cancer patients every year.

In addition to his vision and perseverance, his extraordinary and extensive leadership in the field of Head and Neck Cancer research has been paramount in assuring the best outcomes for cancer patients facing this diagnosis.

Dr. Laramore dedicated much of his career to training Radiation Oncologists who are now delivering radiation therapy to cancer patients throughout the country and the world.  His vision and legacy will continue on through them and, in turn, the physicians they train to treat patients with particle therapy.

Upon learning he had received the NAPT Lifetime Achievement Award, Dr. Laramore stated “I am overwhelmed by NAPT giving me this award, particularly in view of the outstanding Radiation Oncologists who have previously received it. I have spent most of my professional life working with particle radiation of one form or another. While not appropriate for every cancer patient, it is clear to me that there are many patients who can be best served by proton therapy. I am so grateful I have been able to help make this treatment available to them.”

Dr. Herman Suit began practicing while the field of radiation oncology was still in its infancy and served as a key leader in the development of proton therapy as an effective, mainstream tool for treating cancer.

Prior to his work with proton therapy, Dr. Suit graduated from Baylor University with his M.S. and MD, starting medical school at the age of 19. He went on to Oxford University where he studied the use of human bone marrow cellularity and its effect by radiation. He returned to the U.S. as one of a handful of radiation oncologists in the country and practiced at MD Anderson Cancer Center in Houston. There he established fundamental principles in the management of soft tissue sarcomas using radiation and conservative surgery rather than the customary treatment of that time, amputation.

Dr. Suit moved to Boston and became the founding Chair of Radiation Oncology at Massachusetts General Hospital.  He later worked at Harvard University and helped lead the treatment of some of proton therapy’s first patients. The work received funding from the National Cancer Institute in 1972, a research grant that remains active to this day. This early research led to the establishment of proton therapy as a mainstream medical modality.

Among Dr. Suit’s accomplishments are his work with limb-preserving treatment for sarcoma patients and proton treatment for spine, sacral and skull base tumors.

Dr. Suit later served as president of the American Society of Therapeutic Radiation Oncology and president of the Radiation Research Society. He has won numerous awards for his work. These include the Gold Medal of the American Society of Therapeutic Radiation Oncology and American College of Radiology, the Sloan Award for clinical research and two citings as part of “the one hundred” award from the Mass General Cancer Center. In 2017, Dr. Suit was named a Giant of Cancer Care by OneLive in the Radiation Oncology Category.

Dr. James M. Slater has dedicated his entire professional life to promoting, developing, and optimizing proton therapy. He is known as the driving force behind the establishment of the world’s first hospital-based proton treatment center, which opened at Loma Linda University Medical Center (LLUMC) in 1990. What may not be so well known, however, is the magnitude of the work he did to prepare for that event, and the work he has done since then to make proton therapy even more beneficial to the patients it serves.

When Dr. Slater was a radiation oncology resident, in the mid-1960s, he was dissatisfied and distressed with the side effects that often resulted from radiotherapy as it was then practiced. Too many patients suffered unnecessarily, in his view, from too much radiation delivered to too much normal tissue. He resolved to do what he could to reduce unnecessary radiation exposure. Because he had intended to become a physicist before turning to radiation medicine, he knew that heavy charged particles could be a potential tool for reducing side effects, and was aware of the fledgling efforts to use proton therapy in physics research laboratories.

Through the 1970s and early 1980s, Dr. Slater investigated several modalities of heavy-charged-particle radiation therapy. He gradually came to see the proton as the optimal particle for routine radiation oncology, and by the mid-1980s began advocating for a hospital-based proton treatment center. He initiated contacts with Fermilab that led to a collaboration between LLUMC and Fermilab to develop a proton synchrotron and delivery system dedicated to treating patients.

Dr. Slater’s work did not cease after the first hospital-based proton treatment center opened in 1990. In many ways it was just beginning. Recognizing that an ongoing research program is fundamental to making proton therapy as good as possible, he spearheaded efforts to increase proton therapy research. The upshot of this research resulted in the expansion of the list of anatomic sites treated with protons as well as instituting innovative protocols to use protons, such as by means of hypofractionation and combination regimens.

Perhaps the most meaningful effect of Dr. Slater’s work is the benefits it has brought to patients. Judging by the comments he has received from patients, thanking him for the care and caring they received, that commitment still applies. Patients’ gratitude is manifested in many ways, including the formation of an advocacy organization, the Brotherhood of the Balloon (BOB). In appreciation for Dr. Slater’s work, the BOB established an academic chair at LLU in his name. LLUMC itself recognized Dr. Slater’s work in 2007, when the institution re-named the proton facility as the James M. Slater, MD, Proton Treatment and Research Center.

The impact Dr. Slater has had on the field of radiation medicine has benefitted many thousands of patients. He led the way in the routine clinical use of proton radiation. In a lifetime of service, pursued to serve others and yet beneficial to his colleagues, his institution, and the entire field of radiation medicine, he has embodied the best of what it means to be a physician.

Dr. James Cox learned from the masters in the development of radiation as a therapy option for cancer. He went on to become a master himself.

Dr. Cox, a professor emeritus in the Department of Radiation Oncology at the University of Texas MD Anderson Cancer in Houston, brought proton therapy to this world-renowned institution—helping propel the modality into the mainstream. Serving in a variety of capacities at the center, he pioneered ground-breaking research demonstrating proton therapy’s effectiveness for treating a variety of cancers.

Dr. Cox entered the field of radiation oncology in its nascent stages, training under pioneers in the U.S. and Europe including Juan del Regato, Andrée Dutreix, Bernard Pierquin and Jack Maier. After his training, a stint in the military during the Vietnam War and time at Medical College of Wisconsin and Columbia Presbyterian Medical Center, he landed at MD Anderson. First he served as physician in chief and then as head of the radiation oncology division, where he significantly expanded MD Anderson’s cancer treatment program and capabilities.

Introduced to protons in the late 1980s, Dr. Cox was initially not a supporter of the treatment but later stated, “I must admit my shortsightedness, that I didn’t see any particular value for proton therapy.” He ultimately recognized proton therapy as the “natural evolution” of radiation therapy and worked hard to establish a center at MD Anderson. The center began treating patients in 2006.

Bob Marckini hasn’t spent hours with his eye to a microscope, calculated a single proton therapy dosage or reviewed one patient’s CT scan. But patient advocacy has played as important role as medical research in the expansion of proton therapy—and there he has made no small contribution.

After watching his brother suffer the side effects of prostate cancer, Marckini determined to find an alternative to surgical treatment when he received his own diagnosis a few years later. A high-powered, Fortune 500 executive, he did not take the task lightly. He interviewed some 50 prostate cancer survivors and took it upon himself to learn the pros and cons of each therapy alternative.  He ultimately decided that proton beam radiation therapy was the best option for him.

He was treated with proton therapy at Loma Linda University Medical Center—the nation’s first proton therapy clinical center—and emerged its evangelist. “We were blown away,” said Marckini of his initial visit to Loma Linda in an interview with Proton Therapy Today. “And I made my decision right there to get proton therapy treatment.”

After his treatments were complete, Bob and a few fellow patients formed a group in order to stay in touch.  With Bob’s leadership that group ultimately evolved into one of the largest prostate cancer patient advocacy organizations in the world, the Brotherhood of the Balloon (or BOB). The organization provides support to prostate cancer patients around the world while raising money for cancer research. The group has grown from just a few members when it started to now over 10,000 members and continues to grow.

In addition to forming the Brotherhood of the Balloon, Bob later wrote what is still one of the most read books on treatment for prostate cancer. Bob shared that he wrote the book to remove the mystery, confusion, and fear about what to do when you are diagnosed with prostate cancer. In the book, he makes a strong case for proton therapy as a viable option to surgery and other treatment options that often result in debilitating side effects.

It is no exaggeration to call Len Arzt the spokesman for proton therapy.

Mr. Arzt served as senior officer with the Department of Energy’s energy, nuclear medicine, and radiation research programs while proton therapy was still in the commercialization stages and where he recognized its promise as a new and improved radiation treatment for cancer. He later worked at Loma Linda University where the first clinical proton therapy center was established.

In 1990, Mr. Arzt founded the National Association for Proton Therapy as a professional and advocacy organization for the up-and-coming treatment.

With the growth in the number of proton therapy centers nationwide, Mr. Arzt created the NAPT National Proton Conference in 2012. He retired as NAPT’s executive director in December, 2014.